Trevi Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$49.3M | -$51.5M | -$33.9M | -$29.9M | -$32.5M |
| Operating expenses | $49.3M | $51.5M | $33.9M | $29.9M | $32.5M |
| Cash from operations | -$42.1M | -$38.3M | -$31.7M | -$28.2M | -$28.9M |
| Capital expenditure | $12,000 | $35,000 | $137,000 | $159,000 | — |
| Free cash flow | -$42.1M | -$38.3M | -$31.8M | -$28.3M | — |
| Impairments | — | — | — | $0 | $0 |
| Total assets | $193.4M | $110.9M | $89.4M | $123.0M | $38.5M |
| Total liabilities | $10.2M | $11.3M | $6.9M | $15.6M | $21.4M |
Shares outstanding 142.0M · Free float 60.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.